Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CW heads into its November earnings with a fresh analyst cut pulling targets lower, even as the stock itself holds up better than most of its defense peers.
The headline this week came from Citigroup. Analyst John Godyn slashed his price target from $793 to $622 on Wednesday, a cut of 21%, while keeping a Neutral rating. That single move dragged the Street's mean target to $764.88, still well above CW's current price of $553.35, implying roughly 38% nominal upside. The wider analyst picture is mixed but not alarming: Guggenheim initiated with a Buy and a $786 target in mid-September, while Piper Sandler came in at Neutral with a $665 target. Stifel has been steadily raising its Hold target through the year, most recently to $768 in July. The pattern reads as a Street that sees long-term value but is growing more cautious about the near-term path, with the Citigroup cut a sharp reminder that targets set during the summer rally have been revised in light of a stock that has fallen roughly 2.4% over the past month.
The positioning data offers little drama, which is itself part of the story. Short interest is effectively non-existent as a risk factor, at 2.1% of the free float with only a marginal 0.3% increase over the past week. Borrowing shares is almost frictionless: cost to borrow is just 0.31% annually, down 35% week-on-week, and availability is essentially unconstrained. The ORTEX short score sits at 31, a low reading that reflects limited speculative pressure. Options positioning leans slightly defensive, with a put/call ratio of 1.13, just a touch below the 20-day average of 1.17, well within normal range and not flagging any unusual hedging activity. This is not a stock where short sellers or options traders are making a directional statement; the borrow market is relaxed and the lending pool is deep.
The bull case rests on Curtiss-Wright's demonstrated earnings delivery: the company posted 14% year-on-year EPS growth to $3.40 in its last print, with the Defense Electronics segment up 17.5% to $267.3 million, and management subsequently lifted full-year revenue guidance to 10 to 11% growth. Free cash flow conversion of 137% is a clean signal of operational health. The bear case centres on order timing risk, with $50 million in Defense Electronics orders pushed out of Q3 2025 due to continuing resolution uncertainty, and the broader concern that revenue recognition under percentage-of-completion accounting could compress if program timelines shift. The EV/EBITDA multiple of 23x and a P/E of 33x leave limited room for execution misses. Factor scores add nuance: CW ranks in the 74th percentile for EPS surprise, a consistent beat record, but only the 23rd percentile for forward EPS growth momentum, reflecting the Street's more cautious forward estimates.
On relative performance, CW has held its ground better than most correlated peers this week. BWXT and FTAI each rallied sharply on the day, up 7.6% and 8.9% respectively, though both had been softer on the week before Tuesday's move. HWM and MRCY were broadly flat. CW's own 3.6% gain on the week is respectable and consistent with the earlier ORTEX peer note from August, which flagged CW's relative resilience during defense sector selloffs. Institutional ownership remains heavily passive, with BlackRock at 12.3% of shares and State Street adding 70,322 shares in its latest reported period. No activist is on the register.
Insider activity in the window covered is net negative but modest in aggregate. A director sold 100 shares in late August, and the Chief Growth Officer sold 1,035 shares at around $619, both discretionary sales. The one genuine buy came from director Jeffrey Lyash, who purchased 209 shares at $711.62 in August, a price notably above today's level, a fact worth watching as the November 4 print approaches to see whether that conviction is borne out.
The next catalyst is the Q3 earnings release on November 4. With the Citigroup target now sitting below every other Street estimate, and the stock trading at a 28% discount to the pre-cut consensus, the debate heading into that print will centre squarely on whether the order delays flagged in Q3 2025 have fully cleared, and whether Defense Electronics revenue recognition is tracking in line with the bell-curve schedule management described.
See the live data behind this article on ORTEX.
Open CW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
